[{"id":"3211efeb-73ba-4748-919e-faedd3fb0a0b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05091866","created_at":"2024-06-15T04:11:56.215Z","updated_at":"2024-07-02T16:34:27.107Z","phase":"Phase 1","brief_title":"Natural Progesterone for the Treatment of Recurrent Glioblastoma","source_id_and_acronym":"NCT05091866","lead_sponsor":"Emory University","biomarkers":" PGR • CD14 • CHI3L1 • MMP9 • CRP • FCER2","pipe":"","alterations":" ","tags":["PGR • CD14 • CHI3L1 • MMP9 • CRP • FCER2"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 04/11/2022","start_date":" 04/11/2022","primary_txt":" Primary completion: 08/25/2025","primary_completion_date":" 08/25/2025","study_txt":" Completion: 08/25/2026","study_completion_date":" 08/25/2026","last_update_posted":"2024-06-11"},{"id":"4ebdb797-1f50-4cdd-a231-449213daaf19","acronym":"","url":"https://clinicaltrials.gov/study/NCT03941730","created_at":"2021-01-18T19:24:43.568Z","updated_at":"2024-07-02T16:34:59.610Z","phase":"Phase 2","brief_title":"Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer","source_id_and_acronym":"NCT03941730","lead_sponsor":"Mayo Clinic","biomarkers":" HER-2 • PD-L1 • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • PD-L1 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"],"overall_status":"Enrolling by invitation","enrollment":" Enrollment 38","initiation":"Initiation: 08/28/2019","start_date":" 08/28/2019","primary_txt":" Primary completion: 07/31/2026","primary_completion_date":" 07/31/2026","study_txt":" Completion: 07/31/2026","study_completion_date":" 07/31/2026","last_update_posted":"2024-06-03"},{"id":"d6f98f26-2498-46cc-812f-de883aab657a","acronym":"PIONEER","url":"https://clinicaltrials.gov/study/NCT03306472","created_at":"2021-01-18T16:19:53.588Z","updated_at":"2024-07-02T16:35:21.649Z","phase":"Phase 2","brief_title":"A Pre-operative Window Study of Letrozole Plus PR Agonist (Megestrol Acetate) Versus Letrozole Alone in Post-menopausal Patients With ER-positive Breast Cancer","source_id_and_acronym":"NCT03306472 - PIONEER","lead_sponsor":"Cambridge University Hospitals NHS Foundation Trust","biomarkers":" HER-2 • ER • CDH1 • CDH2","pipe":" | ","alterations":" ER positive • HER-2 negative • CDH1 expression","tags":["HER-2 • ER • CDH1 • CDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • CDH1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e letrozole • megestrol"],"overall_status":"Completed","enrollment":" Enrollment 198","initiation":"Initiation: 07/20/2017","start_date":" 07/20/2017","primary_txt":" Primary completion: 10/31/2022","primary_completion_date":" 10/31/2022","study_txt":" Completion: 10/31/2023","study_completion_date":" 10/31/2023","last_update_posted":"2024-01-30"},{"id":"7122b640-e8c3-4f66-a9cf-75e23b76f6c1","acronym":"WinPro","url":"https://clinicaltrials.gov/study/NCT03906669","created_at":"2021-01-18T19:13:54.012Z","updated_at":"2024-07-02T16:35:28.353Z","phase":"Phase 2","brief_title":"A Window of Opportunity Study of Pre-operative Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Breast Hormone Receptor Positive (HR+) Human Epidermal Receptor 2 Negative (HER2-) Breast Cancer.","source_id_and_acronym":"NCT03906669 - WinPro","lead_sponsor":"St Vincent's Hospital","biomarkers":" HER-2 • BCL2 • AR • CCND1 • FOXA1 • CASP3","pipe":" | ","alterations":" HER-2 negative • CCND1 expression","tags":["HER-2 • BCL2 • AR • CCND1 • FOXA1 • CASP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • CCND1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • letrozole"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 03/20/2018","start_date":" 03/20/2018","primary_txt":" Primary completion: 04/01/2024","primary_completion_date":" 04/01/2024","study_txt":" Completion: 04/01/2024","study_completion_date":" 04/01/2024","last_update_posted":"2023-11-22"},{"id":"4415345d-a697-4291-8d70-7d0798eb8ec4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05945407","created_at":"2023-07-14T18:08:53.504Z","updated_at":"2024-07-02T16:35:42.902Z","phase":"","brief_title":"Fertility-sparing Therapy for Patients With Stage IA Endometrial Cancer","source_id_and_acronym":"NCT05945407","lead_sponsor":"Peking University People's Hospital","biomarkers":" TP53 • PTEN • MLH1 • MSH6 • MSH2","pipe":" | ","alterations":" TP53 expression","tags":["TP53 • PTEN • MLH1 • MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e triptorelin • goserelin acetate • megestrol"],"overall_status":"Recruiting","enrollment":" Enrollment 57","initiation":"Initiation: 08/01/2016","start_date":" 08/01/2016","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2023-07-14"},{"id":"3490ad62-c32a-4563-a2d8-c13c52389445","acronym":"","url":"https://clinicaltrials.gov/study/NCT05316467","created_at":"2022-04-07T12:57:05.641Z","updated_at":"2024-07-02T16:35:46.763Z","phase":"Phase 2/3","brief_title":"Weight Management Plus Megestrol Acetate in Early-stage Endometrioid Carcinoma","source_id_and_acronym":"NCT05316467","lead_sponsor":"Xiaojun Chen","biomarkers":" IL6 • TNFA","pipe":"","alterations":" ","tags":["IL6 • TNFA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e megestrol"],"overall_status":"Recruiting","enrollment":" Enrollment 89","initiation":"Initiation: 05/01/2022","start_date":" 05/01/2022","primary_txt":" Primary completion: 02/28/2024","primary_completion_date":" 02/28/2024","study_txt":" Completion: 02/28/2026","study_completion_date":" 02/28/2026","last_update_posted":"2023-05-31"},{"id":"692b5c64-ae80-4b25-ac3f-f2a11e9d83e1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05062174","created_at":"2021-09-30T22:52:56.101Z","updated_at":"2024-07-02T16:35:59.092Z","phase":"","brief_title":"Breast Cancer BRCA1 Carriers: a Pilot Study","source_id_and_acronym":"NCT05062174","lead_sponsor":"Indiana University","biomarkers":" BRCA1","pipe":" | ","alterations":" BRCA1 mutation","tags":["BRCA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mifeprex (mifepristone)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 11/01/2021","start_date":" 11/01/2021","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2022-12-15"},{"id":"cd62df59-cbe8-4f1b-b0fe-9ae110164539","acronym":"MEGA","url":"https://clinicaltrials.gov/study/NCT03024580","created_at":"2021-01-18T14:53:10.909Z","updated_at":"2024-07-02T16:36:56.887Z","phase":"Phase 2","brief_title":"A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer","source_id_and_acronym":"NCT03024580 - MEGA","lead_sponsor":"Instituto Nacional de Cancer, Brazil","biomarkers":" ER • PGR","pipe":" | ","alterations":" PGR positive","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • fulvestrant • letrozole • anastrozole • exemestane • megestrol"],"overall_status":"Unknown status","enrollment":" Enrollment 20","initiation":"Initiation: 03/06/2017","start_date":" 03/06/2017","primary_txt":" Primary completion: 03/01/2020","primary_completion_date":" 03/01/2020","study_txt":" Completion: 09/01/2020","study_completion_date":" 09/01/2020","last_update_posted":"2019-08-15"},{"id":"39d94fa9-761b-4f7d-9a9b-52a865613e4d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03777930","created_at":"2021-01-18T18:41:15.246Z","updated_at":"2024-07-02T16:37:04.517Z","phase":"Phase 4","brief_title":"The Evaluation of Curative Effect on Treatment of Tumor Above Thalidomide Combined With Megestrol","source_id_and_acronym":"NCT03777930","lead_sponsor":"Shenzhen Fifth People's Hospital","biomarkers":" IFNG • IL6 • TNFA • IL2 • IL10 • IL17A • IL21 • IL22","pipe":"","alterations":" ","tags":["IFNG • IL6 • TNFA • IL2 • IL10 • IL17A • IL21 • IL22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e thalidomide • megestrol"],"overall_status":"Unknown status","enrollment":" Enrollment 200","initiation":"Initiation: 12/10/2018","start_date":" 12/10/2018","primary_txt":" Primary completion: 10/10/2020","primary_completion_date":" 10/10/2020","study_txt":" Completion: 06/10/2021","study_completion_date":" 06/10/2021","last_update_posted":"2018-12-19"},{"id":"4aaed04c-a635-4187-8d69-8b930d091ebb","acronym":"","url":"https://clinicaltrials.gov/study/NCT02335203","created_at":"2021-01-18T11:05:13.688Z","updated_at":"2024-07-02T16:37:28.987Z","phase":"Phase 2","brief_title":"The Effect of Neoadjuvant DMPA on Glandular Cellularity in Women Awaiting Hysterectomy","source_id_and_acronym":"NCT02335203","lead_sponsor":"Women and Infants Hospital of Rhode Island","biomarkers":" ER • BCL2 • CASP3","pipe":"","alterations":" ","tags":["ER • BCL2 • CASP3"],"overall_status":"Unknown status","enrollment":" Enrollment 76","initiation":"Initiation: 02/01/2015","start_date":" 02/01/2015","primary_txt":" Primary completion: 03/01/2016","primary_completion_date":" 03/01/2016","study_txt":" Completion: 06/01/2018","study_completion_date":" 06/01/2018","last_update_posted":"2016-09-20"},{"id":"f3410fa7-0ed7-4ba4-85a2-cece33607de0","acronym":"","url":"https://clinicaltrials.gov/study/NCT00064025","created_at":"2021-01-18T00:08:58.739Z","updated_at":"2024-07-02T16:37:32.874Z","phase":"Phase 2","brief_title":"Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus","source_id_and_acronym":"NCT00064025","lead_sponsor":"Gynecologic Oncology Group","biomarkers":" ER • PGR","pipe":" | ","alterations":" PGR positive • PGR expression • PGR negative","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PGR positive • PGR expression • PGR negative"],"overall_status":"Completed","enrollment":" Enrollment 75","initiation":"Initiation: 04/01/2004","start_date":" 04/01/2004","primary_txt":" Primary completion: 09/01/2010","primary_completion_date":" 09/01/2010","study_txt":"","study_completion_date":"","last_update_posted":"2016-04-11"}]